Additional file 1 of Single low dose primaquine to block the transmission of Plasmodium falciparum—proposed stand-alone and ACT-adapted regimens

Additional file 1: Fig. S1 Body weight-normalised clearance of primaquine (14). Fig. S2 Goodness of fit plots for the AUC prediction equation. Fig. S3 The distributions of the nadir haemoglobin (A) and fractional change in haemoglobin (B) from baseline to day of nadir haemoglobin within 14 days in children who received single low dose primaquine or placebo. Fig. S4 Scatter plots of the nadir haemoglobin and fractional change in haemoglobin vs. the maximum primaquine concentration in ng/mL (panels A and B) and primaquine exposure in ng*h/mL (panels C and D). Fig. S5 Gametocyte carriage over time as a function of the mg/kg dose of primaquine. Panel A shows children who received < 0.21 mg/kg and B those received ≥ 0.21 mg/kg. Fig. S6 Scatterplots of the maximum methaemoglobin from days 1 to 3 and the mg/kg dose of primaquine (A), the primaquine Cmax in ng/mL (B), and primaquine exposure in ng*h/mL (C). Fig. S7 Predicted AUCs for single low dose primaquine in ACT-matched and stand-alone regimens. Fig. S8 SLDPQ mg/kg doses of SLDPQ regimens vs. an allometric line. The allometric line formula is adapted from Holford and Anderson (43): primaquine dose = 15 mg × (body weight in kg/60)0.75. Table S1 Baseline characteristics of falciparum-infected Ugandan and Congolese children in the safety trail of single low dose primaquine (6). Table S2 Modelled weight for age Table (8). Table S3 Modelled age for weight Table (8).